# Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)

> **NCT00440297** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 277 (actual)

## Conditions studied

- Hepatitis B Virus Infection

## Interventions

- **BIOLOGICAL:** Comparator: modified process hepatitis B vaccine
- **BIOLOGICAL:** Comparator: ENGERIX-B™

## Key facts

- **NCT ID:** NCT00440297
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440297, "Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00440297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*